BioCentury
ARTICLE | Clinical News

APD515: Phase II started

August 1, 2011 7:00 AM UTC

Acacia began a double-blind, placebo-controlled, crossover, U.K. and Danish Phase II trial to evaluate 20 mg APD515 given 4 times daily for 7 days in about 30 patients. ...